[Problems and perspective approaches to correction of mediator response in sepsis].
Mironov
P I
PI
Rudnov
V A
VA
D018806:APACHE; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002116:Calcitonin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D005786:Gene Expression Regulation; D006023:Glycoproteins / Q000627:therapeutic use; D006360:Heat-Shock Proteins / Q000502:physiology; D006801:Humans; D007167:Immunotherapy; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000502:physiology*; D016209:Interleukin-8 / Q000627:therapeutic use; D008991:Monitoring, Physiologic; D015337:Multicenter Studies as Topic; D009102:Multiple Organ Failure / Q000175:diagnosis / Q000209:etiology; D011498:Protein Precursors / Q000627:therapeutic use; D018805:Sepsis / Q000235:genetics / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D012772:Shock, Septic / Q000276:immunology / Q000628:therapy; D018746:Systemic Inflammatory Response Syndrome / Q000235:genetics / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000900:Anti-Bacterial Agents; D016207:Cytokines; D006023:Glycoproteins; D006360:Heat-Shock Proteins; D018836:Inflammation Mediators; D016209:Interleukin-8; D011498:Protein Precursors; D014409:Tumor Necrosis Factor-alpha; D002116:Calcitonin